Abstract
626 Background: Oral vinorelbine (OV) is a new formulation of well known iv vinorelbine (V). We evaluated the effect of this drug in patients (pts) with advanced breast cancer (ABC) as first line chemotherapy (CT) or beyond first line alone or in combination with trastuzumab (T). Methods: 53 pts (median age: 60 years, range : 38–83) suffering from ABC were treated with OV. 1st line: 24 (45.3%), 2nd line: 18 (34%), 3rd line: 9 (17%), 4th line 1 (1.9%), 5th line: 1 (1.9%). 26 pts underwent prior adjuvant CT (49%), and 34 (64.2%) received prior hormone therapy. Her2-Status was evaluated in all pts. Those positive received a combination of OV and T. 23 pts (43.4%) had bones/soft tissue metastases, 9 (17%) had visceral metastases and 21 (39.6%) had both. The effect of OV was evaluated with CT-scans after three months (m), and treatment was continued until progression. OV was administered at a dose of 60 mg/m2 on day 1 and 8, q 21 days. Results: 25 pts in the OV group are now available for response. We observed...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
